MARGENZA Drug Profile

✉ Email this page to a colleague

Summary for Tradename: MARGENZA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for MARGENZA

Recent Clinical Trials for MARGENZA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Translational Breast Cancer Research Consortium	Phase 2
MacroGenics	Phase 2
Dana-Farber Cancer Institute	Phase 2

See all MARGENZA clinical trials

Pharmacology for MARGENZA

Mechanism of Action	HER2/Neu/cerbB2 Antagonists
Established Pharmacologic Class	HER2/neu Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for MARGENZA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for MARGENZA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for MARGENZA Derived from Patent Text Search

No patents found based on company disclosures

MARGENZA Market Dynamics, Financial Trajectory, Patent Estate, and Generic Risk

Last updated: September 8, 2026

MARGENZA, the brand name for margetuximab-cmkb, is a commercially limited HER2-directed biologic approved for adults with metastatic HER2-positive breast cancer who have received at least two prior anti-HER2 regimens. Its clinical differentiation is an Fc-engineered antibody designed to improve interaction with immune effector cells, but the product has faced a narrow label, intense competition from trastuzumab-based regimens, antibody-drug conjugates, and low commercial scale. Public disclosures indicate that MARGENZA has remained a modest revenue contributor to MacroGenics rather than becoming a major oncology franchise.

What is MARGENZA and how does it compete in HER2-positive breast cancer?

MARGENZA is margetuximab-cmkb, a humanized monoclonal antibody targeting HER2. MacroGenics engineered its Fc region to increase binding to CD16A, an Fc receptor involved in antibody-dependent cellular cytotoxicity, while reducing binding to the inhibitory CD32B receptor.

The FDA approved MARGENZA on December 16, 2020, in combination with chemotherapy for adults with metastatic HER2-positive breast cancer who had received at least two prior anti-HER2 regimens, including at least one for metastatic disease.[1]

MARGENZA product profile

Attribute	MARGENZA
Active ingredient	Margetuximab-cmkb
Sponsor	MacroGenics, Inc.
FDA approval	December 16, 2020
Therapeutic area	HER2-positive metastatic breast cancer
Administration	Intravenous infusion
Dose	15 mg/kg every three weeks
Required combination	Chemotherapy
FDA pathway	Biologics license application
Primary approval basis	SOPHIA Phase 3 trial
Biosimilar pathway	Not applicable to MARGENZA itself; competitors would use the biosimilar pathway if eligible
Commercial status	Commercially marketed biologic with limited market penetration

The approval was based on SOPHIA, a randomized Phase 3 trial comparing margetuximab plus chemotherapy with trastuzumab plus chemotherapy. The trial showed a statistically significant progression-free survival improvement, but the overall survival result was not statistically significant in the primary analysis.[2]

How does MARGENZA compare with HERCEPTIN, ENHERTU, and KADCYLA?

MARGENZA competes in a treatment segment where physicians select among multiple HER2-directed antibodies, antibody-drug conjugates, tyrosine kinase inhibitors, and combination regimens.

Product	Active ingredient	Modality	Typical competitive position
MARGENZA	Margetuximab	Fc-engineered monoclonal antibody	Later-line metastatic disease
HERCEPTIN	Trastuzumab	Monoclonal antibody	Broad HER2 use, including earlier lines and combinations
KADCYLA	Ado-trastuzumab emtansine	Antibody-drug conjugate	Post-surgery residual disease and metastatic disease
ENHERTU	Trastuzumab deruxtecan	Antibody-drug conjugate	Major second-line and later-line competitor
PERJETA	Pertuzumab	Monoclonal antibody	Commonly used in first-line combinations
TUKYSA	Tucatinib	HER2 tyrosine kinase inhibitor	Advanced disease, including brain metastases
NERLYNX	Neratinib	Pan-HER tyrosine kinase inhibitor	Extended adjuvant and selected metastatic use

MARGENZA’s commercial challenge is position rather than lack of biological differentiation. Its label places it after at least two prior anti-HER2 regimens. By that point, treatment decisions are heavily influenced by ENHERTU, KADCYLA, TUKYSA-based combinations, physician familiarity, central nervous system activity, toxicity profiles, and payer controls.

MARGENZA also competes against trastuzumab products that are available through multiple manufacturers, including biosimilars. Those products have expanded price competition across HER2 treatment.

What clinical evidence supports MARGENZA?

The SOPHIA trial enrolled patients with metastatic HER2-positive breast cancer who had received at least two prior anti-HER2 therapies and one to three prior lines of therapy in the metastatic setting.

The trial reported:

Median progression-free survival of approximately 5.8 months with margetuximab plus chemotherapy.
Median progression-free survival of approximately 4.9 months with trastuzumab plus chemotherapy.
A statistically significant progression-free survival benefit.
No statistically significant overall survival benefit in the primary analysis.
Greater potential benefit in patients carrying the lower-affinity CD16A-158F allele, although the FDA label does not limit treatment to that genotype.[1,2]

The efficacy profile supports use as a later-line option, but the modest progression-free survival difference limits MARGENZA’s ability to displace entrenched HER2 products.

What is the financial trajectory of MARGENZA?

MARGENZA has not developed into a high-revenue product for MacroGenics. Sales increased after launch but remained constrained by the late-line label, oncology competition, payer restrictions, and the product’s dependence on chemotherapy combinations.

MacroGenics’ public filings characterize MARGENZA as a commercial product with limited scale relative to the company’s broader licensing, milestone, and pipeline revenue. The company’s total revenue has been materially affected by business-development transactions and royalty or milestone income, making MARGENZA sales an incomplete measure of corporate performance.[3]

Commercial trajectory

Period	Market position	Financial interpretation
2020	FDA approval late in the year	Minimal or no meaningful commercial contribution
2021	Initial U.S. launch	Early adoption, limited oncology account penetration
2022	Expanded commercial experience	Revenue growth from a low base, but still a niche product
2023 onward	Mature late-line positioning	Commercial pressure from antibody-drug conjugates and HER2 biosimilars
Long term	Limited label expansion potential	Revenue depends on retention of later-line use and any new clinical positioning

The product’s revenue exposure is strategically important to MacroGenics but not comparable with blockbuster oncology franchises. MARGENZA’s commercial ceiling is limited by its treatment-line placement and by the availability of products with stronger guideline momentum or broader disease settings.

What factors are pressuring MARGENZA revenue?

Late-line restriction. The product is not approved for first-line HER2-positive disease or early-stage breast cancer.
Antibody-drug conjugate competition. ENHERTU and KADCYLA provide cytotoxic payload delivery and have become central components of HER2 treatment algorithms.
Central nervous system treatment needs. Brain metastases are common in advanced HER2-positive disease. Competing regimens have generated stronger clinical positioning in this area.
Biosimilar price competition. Trastuzumab biosimilars reduce the cost of the comparator class and may influence payer coverage.
Combination dependence. MARGENZA must be administered with chemotherapy, which affects infusion planning, toxicity management, and regimen selection.
Limited differentiation in routine practice. Fc engineering creates a mechanistic distinction, but the clinical benefit over trastuzumab was modest in the pivotal trial.

What patents protect MARGENZA?

MARGENZA is a biologic and its U.S. protection is assessed through patent families, regulatory exclusivity, and biologic reference-product information. Unlike small-molecule drugs, MARGENZA does not have a conventional Orange Book patent listing structure.

The relevant protection categories include:

Composition-of-matter claims covering the engineered anti-HER2 antibody.
Sequence claims covering heavy-chain and light-chain variable regions.
Fc-engineering claims directed to altered Fc receptor binding.
Antibody production and cell-line claims.
Formulation claims covering stable liquid or concentrated antibody formulations.
Method-of-use claims covering treatment of HER2-positive cancer.
Combination claims involving chemotherapy.

The FDA’s Purple Book is the primary public reference for biologic reference products and biosimilar designations. Patent information may also appear in company filings, prosecution records, licensing agreements, and litigation filings.[4]

What is the likely patent expiration profile?

MARGENZA’s earliest relevant U.S. patent rights are expected to extend into the early 2030s, subject to the specific patent family, terminal disclaimers, patent-term adjustment, patent-term extension, claim scope, and validity.

A practical exclusivity assessment is:

Protection category	Expected commercial relevance
Core antibody and sequence claims	Most important barrier to a highly similar competing antibody
Fc-engineering claims	Potentially important, but dependent on claim construction and design-around options
Manufacturing claims	May delay or complicate biosimilar development without blocking all entry
Formulation claims	Can create additional barriers for a commercial presentation
Method-of-use claims	Relevant where the competing label includes the protected indication
FDA biologic exclusivity	Twelve years from first licensure under the Biologics Price Competition and Innovation Act, subject to statutory interpretation and regulatory timing

For a biologic approved in December 2020, the statutory reference-product exclusivity period generally points to December 2032. That date does not necessarily prevent biosimilar filing or development, because the BPCIA allows certain activities before commercial launch, but it can limit the timing of FDA approval and commercial entry.[5]

When does MARGENZA lose exclusivity?

MARGENZA’s key U.S. regulatory exclusivity date is approximately December 2032, based on the FDA approval date and the 12-year reference-product exclusivity framework.

Patent protection may extend beyond, or expire before, the regulatory exclusivity date depending on the specific patent family. A biosimilar applicant could pursue approval before the end of regulatory exclusivity but would generally face restrictions on the commercial launch date.

The most important distinction is:

Regulatory exclusivity: linked to the reference biologic’s first licensure.
Patent exclusivity: depends on individual claims and expiration dates.
Market exclusivity: depends on litigation, settlement, licensing, interchangeability status, payer adoption, and manufacturing readiness.

MARGENZA does not benefit from a small-molecule-style five-year new chemical entity exclusivity period. It is regulated as a biologic under the Public Health Service Act.

What biosimilar risk exists for MARGENZA?

Near-term biosimilar risk appears limited compared with trastuzumab because MARGENZA has a smaller market, a narrower label, and a less established commercial base. Biosimilar development is expensive, and developers usually prioritize biologics with large, durable markets.

Longer-term risk remains material because:

The reference product is a monoclonal antibody with a defined target.
Analytical characterization can support a biosimilar development program.
The core market is oncology, where price competition can be substantial.
A competitor could seek approval for one or more MARGENZA indications through the BPCIA pathway.
The Fc-engineered structure may create additional analytical and clinical comparability work but does not eliminate biosimilar feasibility.

A biosimilar entrant would face manufacturing, comparability, immunogenicity, and clinical pharmacology requirements. The most defensible patent barriers are likely to be the core antibody sequence and Fc-engineering claims, while formulation and process claims may be more susceptible to design-around strategies.

What is the Orange Book and Purple Book status of MARGENZA?

MARGENZA is not a conventional Orange Book-listed small-molecule product. The Orange Book primarily identifies approved drug products and patent or exclusivity information for the Federal Food, Drug, and Cosmetic Act framework.

For MARGENZA, the relevant source is the FDA Purple Book, which identifies:

The reference biological product.
Biosimilar products, if approved.
Interchangeability designations, if granted.
Approval and reference-product information.

As of the product’s early commercial life, MARGENZA did not have an established U.S. biosimilar competitor. No automatic substitution should be assumed without an FDA interchangeability designation and applicable state-law requirements.

Which companies are challenging MARGENZA commercially?

No major commercial challenge has been driven by a named MARGENZA biosimilar competitor comparable to the trastuzumab biosimilar market. The principal competitive pressure comes from branded HER2 therapies and trastuzumab products.

Main competitive companies

Company	Competing product or capability
AstraZeneca and Daiichi Sankyo	ENHERTU
Genentech/Roche	HERCEPTIN, KADCYLA, PERJETA
Pfizer and other biosimilar manufacturers	Trastuzumab biosimilars
Seagen/Pfizer	TUKYSA
MacroGenics	MARGENZA
Multiple oncology companies	Clinical trials in HER2-positive and HER2-low disease

The most significant threat is therapeutic substitution. Physicians do not need to wait for a MARGENZA biosimilar to reduce use of MARGENZA; they can choose another approved HER2-directed therapy at the time of treatment selection.

What patent litigation affects MARGENZA?

There is no widely reported high-value Paragraph IV litigation framework for MARGENZA comparable to litigation surrounding major small-molecule products. Paragraph IV certifications apply to abbreviated new drug applications under the Hatch-Waxman Act. MARGENZA is a biologic, so a biosimilar applicant would proceed under the BPCIA rather than a traditional ANDA Paragraph IV pathway.

Potential disputes could involve:

Patent-listing and patent-disclosure obligations.
Antibody sequence infringement.
Fc-engineering claims.
Formulation patents.
Manufacturing-process patents.
Patent dance compliance.
Declaratory judgment actions.
Launch-at-risk decisions.
Settlement agreements setting an agreed biosimilar entry date.

The absence of a prominent Paragraph IV case does not mean the estate is irrelevant. It means the applicable challenge mechanism is primarily the BPCIA patent process.

What licensing deals support MARGENZA’s commercial position?

MacroGenics has used partnerships and licensing transactions across its pipeline, but MARGENZA’s commercial economics have been primarily tied to MacroGenics’ own product commercialization in the United States rather than a broad global co-commercialization network.

The company’s business-development strategy has included licensing antibody technologies and partnering development programs with larger pharmaceutical companies. Those transactions can create milestone and royalty revenue, but they should not be confused with MARGENZA product sales.

For investors, the relevant distinction is:

MARGENZA provides direct product revenue.
Licensing transactions provide non-product revenue, milestones, and royalties.
Pipeline partnerships can materially affect MacroGenics’ financial statements even when MARGENZA sales are flat or declining.

What generic launch scenarios exist for MARGENZA?

A conventional generic launch is not the relevant scenario. The likely market-entry scenarios are:

Scenario 1: No biosimilar before 2032

MARGENZA remains protected by regulatory exclusivity and patent rights. Commercial performance depends on label retention and physician demand in later-line HER2-positive disease.

Scenario 2: Biosimilar approval with post-2032 launch

A biosimilar enters after reference-product exclusivity, subject to patent settlements and remaining enforceable claims. Price erosion would likely be gradual because the product is administered in oncology infusion settings and lacks the scale of trastuzumab.

Scenario 3: Early settlement-based entry

A biosimilar applicant reaches a settlement that permits entry before the full patent estate expires. The launch could be indication-limited or structured around licensed patent rights.

Scenario 4: Therapeutic displacement without biosimilar entry

MARGENZA loses share to ENHERTU, KADCYLA, TUKYSA combinations, or emerging HER2-directed agents. This is the most immediate commercial risk because it does not depend on patent expiry.

How strong is the MARGENZA patent estate?

The patent estate is likely strongest against direct copies of the specific engineered antibody and weaker against broader therapeutic substitution.

Estate component	Relative strength	Business effect
Specific antibody sequence	High	Direct biosimilar design and infringement risk
Fc-engineered antibody structure	High to moderate	Protects the product’s principal technical differentiation
Broad anti-HER2 method claims	Moderate	May be limited by prior art and claim scope
Chemotherapy combination claims	Moderate to low	Depends on claim drafting and treatment regimen
Formulation claims	Moderate	Can delay use of the commercial presentation
Manufacturing claims	Moderate	Raises development cost but may be designed around

The estate should be viewed as a layered defense rather than a single blocking patent. Its practical value depends on remaining term, claim validity, enforceability, and the ability of a biosimilar developer to avoid infringement while maintaining analytical similarity.

What geographic markets and manufacturing barriers matter?

MARGENZA’s commercial value is concentrated in markets with:

Reimbursement for later-line HER2-positive metastatic breast cancer.
Established infusion infrastructure.
Access to companion chemotherapy.
Recognition of Fc-engineered antibody differentiation.
Favorable oncology formulary placement.

Manufacturing barriers include mammalian cell-culture production, purification, viral clearance, glycosylation control, Fc characterization, stability testing, and comparability requirements. Fc engineering increases the analytical burden because a biosimilar developer must demonstrate similarity in receptor binding and functional activity, not only target binding.

Those barriers can reduce the number of credible competitors but do not provide permanent protection. Large biologics manufacturers and experienced biosimilar companies have the technical infrastructure to reproduce complex monoclonal antibodies.

Key Takeaways

MARGENZA is a later-line HER2-positive metastatic breast cancer biologic approved in December 2020.
Its differentiation is Fc engineering intended to improve immune-effector activity.
SOPHIA demonstrated a modest progression-free survival improvement versus trastuzumab, without a statistically significant overall survival benefit in the primary analysis.
Commercial potential is constrained by the late-line label and competition from ENHERTU, KADCYLA, HERCEPTIN, trastuzumab biosimilars, and TUKYSA-based regimens.
MARGENZA is governed by biologic and BPCIA rules, not a conventional Orange Book Paragraph IV framework.
Reference-product exclusivity generally points to approximately December 2032.
The core antibody, Fc-engineering, formulation, manufacturing, and method-of-use patent families form the principal protection layers.
The immediate risk is therapeutic substitution, while direct biosimilar risk is more likely to become relevant near or after the early 2030s.
MARGENZA has remained a modest revenue contributor to MacroGenics compared with the financial impact of licensing transactions and pipeline milestones.

FAQs

Is MARGENZA a biosimilar of HERCEPTIN?

No. MARGENZA is a distinct Fc-engineered monoclonal antibody. It is not a trastuzumab biosimilar and has its own biologics license.

Can MARGENZA be used as first-line HER2-positive breast cancer therapy?

No. The FDA label is for patients with metastatic HER2-positive breast cancer who have received at least two prior anti-HER2 regimens, including at least one for metastatic disease.

Does MARGENZA have an Orange Book patent listing?

MARGENZA is a biologic, so the Purple Book and BPCIA framework are more relevant than a conventional Orange Book listing under Hatch-Waxman.

What is the main commercial threat to MARGENZA?

The main threat is therapeutic substitution by antibody-drug conjugates, especially ENHERTU and KADCYLA, rather than immediate entry by a MARGENZA biosimilar.

What is the expected MARGENZA exclusivity date?

The statutory reference-product exclusivity period generally indicates December 2032, based on the December 2020 first licensure date. Patent claims may have different expiration dates.

References

U.S. Food and Drug Administration. (2020). FDA approves margetuximab for metastatic HER2-positive breast cancer. https://www.fda.gov
Rugo, H. S., Im, S. A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., et al. (2021). Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer: A phase 3 trial. JAMA Oncology, 7(4), 573-584.
MacroGenics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119 (2010).

More… ↓

⤷ Start Trial